Eli Lilly and Sigilon Therapeutics have announced a collaboration to develop therapies based around capsules of genetically-engineered stem cells to treat type 1 diabetes.
Novo Nordisk can add data showing Tresiba can reduce the risk of hypoglycaemia to its label, a development which should help its fight competition from cheaper alternati
